论文部分内容阅读
目的检测RKIP(Raf激酶抑制蛋白)在人前列腺癌组织中的表达,并分析其与前列腺癌病理分级、临床分期的关系。方法运用免疫荧光组织化学的定量方法,检测26例PCa组织和14例BPH组织中RKIP的表达情况,并分析其与前列腺癌病理分级、临床分期的关系。结果RKIP在前列腺癌组织中的表达较前列腺增生组织显著下降;在前列腺癌组织Gleason 8～10分的分化不良组中的表达较Gleason 5～7分的分化良好组明显下降;在前列腺癌组织T_2N_0M_0以内的无转移组中的表达较侵袭转移组明显下降。结论RKIP是一种新型的前列腺癌转移抑制基因,其表达的上调能促进前列腺癌的分化,抑制前列腺癌的转移。
Objective To detect the expression of RKIP (Raf kinase inhibitor) in human prostate cancer and to analyze its relationship with the pathological grade and clinical stage of prostate cancer. Methods The expression of RKIP in 26 cases of PCa and 14 cases of BPH was detected by immunofluorescence histochemistry. The relationship between the expression of RKIP and the pathological grade and clinical stage of prostate cancer was analyzed. Results The expression of RKIP in prostate cancer tissues was significantly lower than that in benign prostatic hyperplasia tissues. The expression of RKIP in dysplasia tissues of 8-10 of Gleason prostate cancer tissues was significantly lower than that in well-differentiated Gleason 5-7 groups. In prostate cancer tissues T_2N_0M_0 Within the non-metastasis group than the invasion and metastasis decreased significantly. Conclusion RKIP is a new type of prostatic cancer metastasis suppressor gene whose upregulation can promote the differentiation of prostate cancer and inhibit the metastasis of prostate cancer.